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Introduction 
The haemostatic response could be considered a defens- 
ive function: it prevents or avoids blood loss from 
damaged vasculature (haemorrhage) and ensures 
adequate blood flow, maintaining the vascular tree free 
of obstruction (thrombosis). Procoagulant activity 
(inactive haemostatic proteins) is modulated or 
inhibited by several mechanisms. Endothelial cells play 
a key role in the control of these functions. The 
adequate quilibrium between activation and inhibition 
of haemostasis depends on interactions between 
endothelial cells, platelets, circulating blood cells, 
coagulation activators and inhibitors. 
Disseminated intravascular coagulation (DIC) may 
represent loss of haemostatic equilibrium - induced by 
numerous clinical entities - resulting in life-threatening 
consequences. 
This review summarises the data recently obtained 
concerning the aetiology, pathophysiology, clinical 
findings and laboratory diagnostics as regards DIC. 
Current and future DIC diagnostic and treatment 
modalities are discussed. It should be realised at the 
outset that disease presents differently among a con- 
tinuum of events. Patients may undergo DIC anywhere 
in this continuum and, depending on the position in the 
continuum, exhibit radically different clinical and 
laboratory effects. 
Correspondence and offprint requests to: Dr B. F. Feldman, Compara- 
tive Hemostasis Laboratory, Department of Biomedical Sciences 
Virginia Maryland Regional College of Veterinary Medicine, Virginia 
Polytechnic Institute, Blacksburg, VA 24061--0442, USA. 
Terminology 
Disseminated intravascular coagulation (DIC), is also 
known as consumptive coagulopathy, an inappropriate 
descriptor because, although some coagulation proteins 
(factors and inhibitors) are consumed, many factors and 
other plasma constituents are biodegraded by plasmin 
(Jandl 1991). Another descriptor, defibrination syn- 
drome, would be more appropriately retitled 'defibrino- 
genation syndrome', because fibrinogen is both 
consumed and biodegraded. Therefore, the term dis- 
seminated intravascular coagulation is given preference 
- it describes the dynamic process of disseminated 
coagulation taking place intravascularly - expressed as 
both haemorrhage and thrombosis (Feldman 1981; 
Slappendel 1988b). DIC is obviously expressed by 
haemorrhagic diatheses. But, DIC is also associated 
with diffuse thrombosis (and is sometimes called diffuse 
intravascular thrombosis; DIT) leading to impairment 
of blood rheology, ischaemia nd multiorgan failure, 
perhaps causing irreversible damage and, ultimately, 
patient mortality. 
Aetiology 
DIC is associated with numerous clinical conditions 
(Table 1). Depending on the activation rate of the 
haemostatic system, DIC may occur as an acute and life- 
threatening event or as a chronic form without severe 
thrombosis and haemorrhage. DIC may be initiated by 
a single cause or by multiple causes occurring sequen- 
tially or simultaneously. The anticipated events induc- 
ing DIC - in most conditions - are related to: 
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Table 1. Conditions associated with disseminated intravascular 
coagulation 
Table 2. Bacteria and viruses incriminated in disseminated intra- 
vascular coagulation 
A. Intravascular haemolysis 
Haemolytic transfusion reactions 
Haemolytic anemia 
B. Septicaemia (Table 2) 
Gram negative (endotoxin) 
Gram positive (bacterial coat 
mucopolysaccharide) 
C. Viraemia (Table 2) 
D. Parasitic infections 
P, totozoal infection 
Metazoal infection 
E. Obstetric omplications 
F. Miscellaneous 
Gastric dialtation/volvulus 
Diabetes mellitus 
G. Malignancy (Table 3) 
H. Massive tissue injury 
Trauma 
Burns 
Surgical procedures 
Heat stroke 
I. Venoms and Toxins 
Snake bite 
Bee/insect sting 
Aflatoxin (see J.) 
J. Liver disease 
K. Pancreatitis 
1. Tissue factor (TF) or thromboplastin-like substances 
liberated into the circulation; 
2. Damaged endothelia/monocytes converting proco- 
agulants into active forms (activated procoagulants); 
3. Blood flow interruption preventing hemodilution of 
activators; 
4. Impaired removal of activated procoagulants bythe 
liver. 
Intravascular Haemolysis 
Intravascular haemolysis i a considerable trigger for 
DIC. The acute haemolytic transfusion reaction repre- 
sents a major DIC stimulus. The release of erythrocytic 
adenosine diphosphate (ADP) and/or membrane phos- 
pholipoproteins may directly stimulate platelet aggre- 
gation and coagulation (Bick 1985; Borrego et al. 1991). 
Even transfusion of autologous haemolysed blood was 
found to cause decrease in factors X, VIII, fibrinogen 
and to cause pulmonary arterial thrombosis in dogs 
(Cotter 1992). 
Infectious Agents 
DIC has been reported in association with many 
infectious agents (Table 2) including numerous Gram- 
negative and Gram-positive organisms (Stein and 
Libertin 1990; Morris 1991). Bacterial coat lipopolysac- 
charide (LPS) released as a result of proliferation or 
lysis of Gram-negative bacteria (endotoxin), has the 
ability to initiate DIC (Warr et al. 1990) by direct 
activation of endothelium, the contact system (the kinin 
system and factors XII and XI), complement, leuco- 
cytes and platelets (Ewert et al. 1985; Moher 1988). 
Gram-positive bacteria have mucopolysaccharide coats 
which may induce DIC by the same mechanisms noted 
with endotoxins. Septicaemia due to bacterial infection 
Bacteria  Viruses b
Gram-negative bacteria 
Escherichia coli 
Pasteurella hemolytica 
Pasteurella multocida 
Salmonella species 
Gram-positive bacteria 
Staphylococcus species 
Streptococcus species 
Clostridium species 
Mycobacterium species 
Infectious canine hepatitis 
Canine distemper 
Canine herpes virus 
Feline infectious peritonitis 
Feline panleukopenia 
Hog cholera 
African swing fever 
Blue tongue 
Epizootic haemorrhage ofdeer 
Fowl plague 
Viral haemorrhagic disease of 
rabbits 
a Ellison et al. (1988), Kiper and Paulsen (1988), Isogai et al. (1989), 
Bowersock et al. (1990), Braun et al. (1990), Kokosharov et al. 
(1990), Stein and Libertin (1990), Morris (1991), Anderson et al. 
(1992). 
b Ward and Conway (1980), Howerth et al. (1988), Pan et al. (1988), 
Greene (1990), Greene and Scott (1990), Huang (1991). 
is accompanied by acidosis which may provide an 
independent trigger for DIC (Bick 1985). However, the 
clinical presentation is probably the summation of 
several or all of these activation events. 
Viruses 
Viruses responsible for triggering DIC may do so by 
involvement in associated circulating antigen-antibody 
complexes which activate the endothelium and possibly 
the contact system. Viruses can also induce the platelet 
release reaction (Bick 1985; Cosgriff 1989; Studdert 
1994). 
Parasitic Infections 
Protozoal infections uch as trypanosomiasis (Olubayo 
and Mugera 1985; Suliman and Feldman 1989), 
babesiosis (Krooshof et al. 1984; Blood and Radostits 
1989), and sarcocystosis (Frelier and Lewis 1984; 
Daugschies et al. 1989) may induce DIC. 
Metazoal infection associated with DIC is exempli- 
fied by heartworms in dogs (Dillon and Braund 1982). 
The vascular damage induced by these blood parasites 
and the associated embolic phenomena causes release 
of tissue thromboplastin, the key to triggering DIC in 
heartworm patients (Kociba and Hathaway 1974; 
Cooley et al. 1987). 
Obstetric Complications 
Obstetric complications commonly trigger DIC 
(Seegers 1971). DIC may occur in association with 
dystocia, eclampsia, Caesarean section, and retained 
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fetal placenta (Dodds 1985; Braun et al. 1990). A 
physiological potential hypercoagulable state has been 
reported to be associated with parturition (Murano and 
Bick 1980; Gentry et al. 1991). The proposed mechan- 
isms that initiate DIC in obstetric complications 
include: (1) the release of amniotic fluid (with activity 
similar to thromboplastin, platelet factor 3 or phospho- 
lipoprotein into maternal circulation) (Lockwood et al. 
1991; Parihar et al. 1991); (2) release of placental 
enzymes or tissues with thromboplastin-like activity into 
the maternal circulation (Bick 1985; Braun et al. 1990; 
Wagner et al. 1990; Suchartwatnachai et al. 1991); and 
(3) release of necrotic fetal tissue or enzymes (with 
activation of the maternal haemostasis) into the mater- 
nal circulation (Angelov 1989; Bosner et al. 1989; Braun 
et al. 1990). 
Miscellaneous 
DIC has been identified as an important complication 
that affects both mortality and morbidity in gastric 
dilatation-volvulus patients (Drazner 1982). The 
damaged organs release large amounts of thrombo- 
plastins into the circulations; local acidosis may occur 
leading to DIC (Hall 1972; Lippincott and Schulman 
1989). Acidosis triggers DIC through sloughing of 
endothelial cells and subsequent activation of the 
contact system (Baker 1989). 
In diabetic patients DIC may be initiated by injury of 
the vascular endothelium (Bick 1979), peripheral capill- 
ary stasis (Bick 1982, 1985), microangiopathy, and 
enhancement of platelet aggregation (Titova et al. 1989; 
Barnett 1991). 
Malignancy 
Malignancy isreported as the underlying disease in 39% 
of dogs diagnosed with DIC (Feldman et al. 1981). 
Haemangiosarcoma, disseminated carcinomas, haema- 
topoietic and lymphoreticular tumours are commonly 
associated with DIC in small animals (Helfand 1988; 
Hammer et al. 1991; Hargis and Feldman 1991). DIC 
has been suggested as the major pathophysiological 
mechanism underlying microangiopathic haemolytic 
anaemia (MAHA) often associated with malignancy in
small animals (Helfand 1988; Slappendel 1988a). The 
presence of large tumour burdens or tumours associated 
with bone marrow, spleen or liver (specifically wide- 
spread infiltration - haemangiosarcoma, lymphosar- 
coma or leukaemia) are conditions associated with 
MAHA in dogs (Madewell and Feldman 1980; Rebar et 
al. 1980). There are five possible mechanisms that 
trigger DIC in cancer patients and these are listed in 
Table 3. Some cancer patients develop typical DIC with 
secondary fibrinolysis and/or primary activation of 
fibrinolysis that overwhelms the fibrinolytic inhibitor 
response. In cancer patients, subclinical compensated 
DIC is more common than either compensated DIC 
Table 3. Mechanisms that incite disseminated intravascular coagu- 
lation in cancer patients 
1. Stimulation of the coagulation cascade 
(a) Cancer cells induce platelet activation and aggregation 
(Hammer et al. 1991; Hargis and Feldman 1991; Suchartwat- 
nachai et al. 1991). 
(b) Cancer cells release thromboplastin a d/or other procoagulant 
factors (PCA) that enhance coagulation (Madewell and Feld- 
man 1980 Helfand 1988; Slappendel 1988a). 
(c) Cancer cells stimulate macrophages and monocytes to release 
PCA factors (Rebar et al. 1980; Radomski et al. 1991). 
(d) Cancer cells release a specific factor X activator, a cysteine 
protease known as cancer PCA factor which is released by a 
variety of malignant cells including breast, liver, renal and, 
lung carcinomas, undifferentiated sarcomas, liposarcomas, 
melanomas (Edwards et al. 1990; Spearman et al. 1991). 
(e) Non-enzymatic activation of factor X by the sialic moiety of 
mucin in mucinous adenocarcinomas (Mohanty et al. 1991). 
2. Vascular damage by neoplastic growth or vascular damage of 
vessels within neoplastic tissues might lead to exposure of suben- 
dothelial collagen (Rebar et al. 1980). 
3. Enhancement of the haemostatic system by complications of 
malignancy such as surgery, chemotherapy and sepsis (Rebar et al. 
1980). 
4. Decrease hepatic synthesis of antithrombin III (AT III), and 
protein C in metastatic cancer (Gordon 1984; Clouse and Comp 
1986; O'Keefe and Couto 1988; Lefrere et al. 1989; Roncaglioni et 
al. 1989; Clauss et al. 1990; Irimura et al. 1990; Kubota et al. 1991). 
5. Activation of the fibrinolytic ascade by a plasminogen activator 
(urokinase-like) (Clauss et al. 1990) or a tissue-type plasminogen 
activator released from some tumour cells (Jones et al. 1980; Giger 
and Gorman 1984; Badenoch et al. 1986; Camiolo and Greco 1986; 
Kapina et al. 1986; Duffy 1990; Reilly et al. 1991). 
with thrombosis or uncompensated DIC leading to 
haemorrhage (Madewell and Feldman 1980; Giger and 
Gorman 1984). Haemorrhagic DIC has been seen with 
various tumours including thyroid carcinoma, hae- 
mangiosarcoma, mammary carcinoma, intrathoracic 
carcinoma, and adrenal tumour (Jones et al. 1980; 
Green 1981; O'Keefe and Couto 1988). In contrast o 
humans, DIC appears to be uncommon in dogs with 
leukaemia. It has been suggested that DIC may 
complicate leukaemia in cats (Kobilinsky et al. 1979; 
Jacobse-Geels etal. 1980). 
Traumatic Shock 
Traumatic shock is a well-recognised cause of DIC 
(Hardaway 1981; Ordog and Wasserberger 1986). 
Thromboplastic substances are released from trauma- 
tised tissue into the circulation, precipitating the devel- 
opment of DIC. In addition, the decreased flow of 
capillary blood induced by hypovolaemia is a contribut- 
ing factor (Hardaway 1980a,b). Clinical and laboratory 
evidence indicate that the passage of blood through 
traumatised tissue causes erythrocyte lysis triggering 
coagulation (Hardaway and Williams 1987, 1990). The 
release of cellular enzymes in combination vasoactive 
substances already in the circulation also contribute to 
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the induction and perpetuation of DIC (Hardaway 
1980a; Ordog and Wasserberger 1986; Hardaway and 
Williams 1990). As the fibrinolytic system is also 
activated both microthrombi and haemorrhage may be 
observed (Hardaway 1981). 
DIC may occur subsequent to bone fracture and 
fracture surgery. The direct release of large amounts of 
lipids and tissue thromboplastin from fractured bones 
into the circulation initiates hypercoagulability in some 
patients (Buntain 1980; Raphael 1982). All surgical 
procedures activate the haemostatic system. This is 
especially true of prolonged abdominal surgical 
procedures (Buntain 1980; Lipowitz 1985). 
Thermal injuries are relatively uncommon in 
domestic animals, especially large animals. Severely 
affected patients commonly develop DIC, with several 
mechanisms operative (Johnston 1985; Iashvili et al. 
1986; Ono 1987). DIC in burned animals presumably 
results from both haemolysis and tissue necrosis and 
release of tissue components, cellular enzymes, and 
phospholipoprotein-like materials into the circulation 
(Bick 1982). The aetiology of DIC in the early stages 
after thermal injury remains unclear. However, massive 
thrombin generation and decrease of anticoagulant 
activity, mainly antithrombin III (ATIII) concentra- 
tions, have been observed (Goodwin 1989; Ueyama et 
al. 1991). 
Heat stroke can directly provoke DIC by widespread 
vascular and tissue damage (Drazner 1982; Holman and 
Schneider 1989). 
factor X (Bothrops atrox) or factor II (Wintrobe et al. 
1981). Echis carinatus venom was found to rapidly 
induce DIC in mongrel dogs by direct activation of 
prothrombin (Schaeffer et al. 1986). The venom of 
Pseudonaja textilis textilis - an Australian snake - 
contains prothrombinase. This converts prothrombin 
into cr-thrombin directly, resulting in fibrinogen degra- 
dation (Masci et al. 1990). Crude venoms also contain 
substances that act as thromboplastins and produce 
intravascular red cell lysis and massive vascular endo- 
thelial damage (Wintrobe et al. 1981). Hymenoptera 
(bees, wasps and hornets) stings in dogs result in acute 
DIC which can be fatal, or more chronic forms of DIC 
(Cowell et al. 1991). DIC is initiated by Hymenoptera 
venom which includes components such as phospholi- 
pase A, histamine, acetylcholine, serotonin and kinins. 
Pancreatitis 
Pancreatitis may trigger DIC by activation of trypsin, 
kallikrein (KK) and phospholipase A2 in the pancreatic 
(and surrounding) tissue (Uehara et al. 1989; Williams 
1989). These enzymes have thrombin-like activity or 
factor Xa-like activity which results in activation of the 
haemostatic system and DIC. The release of leucocyte 
elastase during pancreatitis has the capacity to degrade 
plasma proteins such as o:2-antiplasmin, ATIII and 
factor XIII. This protein degradation may cause more 
tissue damage and can further potentiate DIC (Axels- 
son et al. 1990). 
Liver Disease 
Development of DIC is a common event in severe 
hepatopathy in dogs and cats (Green 1989). Impairment 
of hepatic synthesis of coagulation proteins or impaired 
hepatic learance functions may manifest as thrombotic, 
fibrinolytic or haemorrhagic complications (Hersch et 
al. 1987; Green 1989). The enhanced plasmin gener- 
ation noted in liver disease promotes activation of the 
kinin system causing hypotension, shock and end-organ 
damage, as well as biodegradation of coagulation 
factors by plasmin (Kaplan and Silverberg 1987). 
Failure of clearance of fibrin(ogen) degradation 
products (FDPs) by the diseased liver will allow FDPs 
to further impair fibrin polymerisation and platelet 
aggregation (Drazner 1982). Ingestion of aflatoxin 
contaminated dog food has been reported to cause DIC 
(Hagiwara et al. 1990). The resultant severe hepatocel- 
lular degeneration a d necrosis is sufficient o initiate 
DIC through extensive release of tissue thromboplastin 
(Baker and Green 1987). 
Venoms and Toxins 
Snake venoms contain enzymes that may trigger 
haemostasis in unique ways. Venoms contain thrombin- 
like enzymes or substances that specifically activate 
Pathophysiology (Fig. 1) 
Disseminated intravascular coagulation may be con- 
sidered an uncontrolled burst of thrombin generation 
and activity. This massive activation overwhelms 
haemostatic inhibitors, depletes procoagulants and 
platelets, induces thrombosis, and as a final result 
tissues are severely damaged. Thrombus formation and 
subsequent ischaemia nd necrosis may activate an 
enhanced fibrinolytic response which would impair 
platelet function and deplete coagulation factors 
(Schrier 1993). 
The inflammatory response has important inter- 
actions with haemostasis, may activate haemostasis or
impair its inhibition. Recent studies, have described 
some of these interactions. 
1. Neutrophil activation and degranulation liberates 
lactoferrin, a prominent component of neutrophil 
secondary granules. Lactoferrin is an iron-binding 
protein and thus has a physiological role in the regu- 
lation of inflammation and other host defence mechan- 
isms. Lactoferrin has potent heparin-neutralising 
activity during thrombin inhibition by serine proteinase 
inhibitors ATIII and heparin cofactor II. It has been 
observed that specific inflammatory mediators as 
tumour necrosis factor-or (TNF-o 0 increased the concen- 
tration of both platelet factor 4 (PF-4), which inhibits 
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heparin, as well as plasma lactoferrin (Wu et ai. 1995). 
Activated neutrophils adhere to endothelium and 
release elastase which cleaves and may inactivate 
thrombomodulin (TM) (Esmond 1994). Platelet 
aggregation may be induced by activated neutrophils, 
mediated by platelet activating factor-acether (PAF- 
acether). PAF is a phospholipid produced by vascular 
endothelium, platelets and monocytes (Nguyen et al. 
1995). 
2. The cytokines TNF-o: and interleukin 1(IL-1), may 
initiate the endothelial expression of adhesion mole- 
cules (one of which is E-selectin; others have yet to be 
identified) that bind monocytes and neutrophils. P- 
selectin requires thrombin activation to be mobilised 
from endothelial Weibel-Palade bodies. This fact may 
involve platelet adhesion to endothelial cells and mono- 
cytes, and could serve as a focal point to amplification 
reactions involved in thrombin generation (Edmond 
1994). 
3. Complement terminal components C5b-9, induce a 
procoagulant activity in platelets. Coagulation factors 
can adhere to negatively charged phospholipids such as 
phosphatidylserine, which normally, is not exposed on 
the surface of inactivated platelets. It is suggested that 
platelet activation may induce membrane vesiculation 
and formation of microparticles. This may be con- 
sidered a critical component of prothrombin activation 
(Esmond 1994; Sandberg et al. 1985). 
The contact system includes factors XII (FXII) and 
XI (FXI) and the kinins. Activation of the contact 
system occurs through contact with negatively charged 
surfaces, cerebroside sulphates, glycosaminoglycans, 
plasmin, hypersensitivity/anaphylactic rea tions, and 
lipid A component of endotoxins (Wachtfogel et al. 
1993). The consequences are: 
1. Coagulation factors VII and XI are activated (by 
FXIIa); 
2. Complement fraction C1 is activated (by FXIIa); 
3. Prourokinase and plasminogen are activated by 
FXIIa and kallikrein; 
4. Neutrophils are activated by FXIIa and kallikrein; 
5. Kininogens increased the activation of FXI, but 
inhibit cellular adhesion to endothelium (monocytes, 
neutrophils and platelets). In addition, bradykinin 
increases vascular permeability and hypotension. 
Endothelial cells and monocytes may express tissue 
factor when these cells are exposed to endotoxins, IL-1 
and TNF (Esmond 1994). The formation of factor VII- 
TF complexes induces factor X and factor IX activation. 
The inhibitory activity of tissue factor pathway inhibitor 
(TFPI) may possibly be overwhelmed if TF exposure is
extensive. Furthermore, the experiment administration 
of human recombinant TFPI in animal models of endo- 
toxin-induced shock reduced mortality. The inhibitory 
activity of TFPI on inflammatory response is also 
suggested because lower concentrations of IL-6, were 
found in these animals (Taylor 1994; Petersen et al. 
1995). 
Endothelial damage caused by circulating antigen- 
antibody complexes, endotoxaemia, or other forms of 
tissue damage can change the endothelial cell anti- 
coagulant phenotype. This results in a massive pro- 
coagulant fibrinolytic ounterattack onthe luminal side 
of the endothelial cell through the expression of TF and 
release of tissue plasminogen activator (tPA) (Taylor 
1994). Trauma nd haemolysis may also liberate TF into 
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the circulation (Mant and King 1979; Slappendel 1988b; 
Muller 1989; Nakamura et al. 1990). When one of these 
insults occurs, there are many potential elements for 
uncontrolled generation of circulating thrombin and 
plasmin. Circulation of these two enzymes ystemati- 
cally may be considered DIC. Despite the differing 
activation pathways by which thrombin and plasmin are 
generated, the resultant pathophysiology of DIC 
basically remains the same (Mant and King 1979; 
Slappendel 1988b). 
Thrombin activates the protein Cpathway. The early 
activation of protein C (and subsequent consumption) 
in-sepsis has been observed in human patients. Throm- 
bin bound to TM - an endothelial cell surface receptor- 
activates protein C, and results in feedback inhibition of 
thrombin (thrombin loses its coagulant effect). Acti- 
vated protein C (APC) bound to the cofactor protein S, 
cleaves FVa and FVIIIa. Protein S circulates free or 
bound to C4b binding protein (C4bBP), an inhibitor of 
complement (and at the same time an inhibitor of the 
protein C pathway). Activated PC is inhibited by 
protein C inhibitor (PCI) - a heparin-dependent 
reaction - and a:l-antitrypsin. Protein C inhibitor also 
binds KK. KK may also play a regulatory role in protein 
C activity (Alcaraz et al. 1995). The effect of cytokines 
on the protein C pathway has been studied, especially 
related to septic shock. It has been observed that infants 
with protein C deficiency may develop purpura ful- 
minans. Patients with severe septic shock present with 
similar cutaneous lesions which resemble this process 
(Walsh et al. 1991). Thereafter, C4bBP behaves as an 
acute phase reactant which can reduce free protein S 
concentrations (Esmond 1994). Endotoxins and cyto- 
kines (IL-1 and TNF) also downregulate TM expression 
(Edmond 1994). In conclusion, coagulation i hibition is 
severely impaired potentiating thrombus formation. 
Thrombin activates FV, FVIII:C and FXIII and 
cleaves fibrinopeptides A and B from fibrinogen to yield 
fibrin monomers. The monomers polymerise into fibrin 
clots. This leads to microvascular nd macrovascular 
thrombosis and ensuing ischaemia nd organ failure 
(Muller 1989; Jandl 1991). Thrombin also binds 
irreversibly to platelets promoting platelet adhesion to 
endothelial cells, platelet aggregation, and induces 
secretory release of platelet r and dense granule con- 
tents (Nomura et al. 1991; Venturini and Kaplan 1992). 
ADP and thromboxane A2 (TxA2) release will further 
accelerate platelet aggregation causing amplification of 
coagulation processes and thrombin generation. Plate- 
lets are trapped in micro- or macrothrombi. This results 
in the clinical manifestations of thrombocytopenia 
(Feldman 1981; Feldman et al. 1988; Jandl 1991). 
Plasmin is generated by the enzymatic conversion of 
circulating plasminogen (a proenzyme, synthesised by 
kidneys, liver and eosinophils). Tissue PA is secreted by 
injured endothelium and macrophages near the injured 
area, and contact system activation also contributes to 
plasmin generation. Plasmin is capable of hydrolysing 
not only fibrin and fibrinogen but also other proteins 
such as factors V, VIII, IX, XI, insulin, ACTH, casein 
and gelatin (Muller 1989; Jandl 1991). Digestion of 
fibrinogen by plasmin results in fibrin(ogen) degra- 
dation products (FgDP) composed of fragments X, Y, 
D and E (Muller 1989). FDPs in the circulation interfere 
with fibrin monomer polymerisation (basically by 
inhibiting fibrin polymerisation and blocking the 
receptor sites of fibrinogen on thrombin) causing 
further amplification of fibrinolysis, impairment of 
haemostasis and, resultant haemorrhage (Feldman 
1981; Muller 1989; Jandl 1991). Other FDPs (fragments 
D and E) have high affinity for platelet membranes, 
inducing platelet dysfunction through granule release 
and platelet aggregation inhibition (Wintrobe et al. 
1981). This contributes to clinical haemorrhage. Thus, 
systemic release of FDPs in large quantities also con- 
tributes to some of the bleeding problems encountered 
in patients with DIC. Plasmin is capable of activating 
the complement system (C1 and C3), and contributes to
the activation of the contact system. Subsequent 
neutrophil activation, red cells iysis, platelet activation 
and/or lysis results (Muller 1989; Carroll et al. 1990; 
Nomura et al. 1991). Damage to both red cells and 
platelets provides more substrate in the form of pro- 
coagulant materials accentuating thrombocytopenia. 
Activation of the complement system and BK affects 
the endothelium, enhancing vascular permeability 
ultimately leading to hypotension and shock. 
In summary, inflammation activates haemostasis 
through neutrophil activation (inducing platelet 
aggregation, inactivation of heparin-dependent serine 
proteases and the protein C pathway), monocyte 
expression of TF, complement activation (inducing 
platelet procoagulant activity) and cytokine release 
(which induces endothelial TF expression and endo- 
thelial changes more receptive to coagulation). 
Activation of the contact system has several con- 
sequences: coagulation activation, activation of 
fibrinolysis, complement activation, neutrophil acti- 
vation, and kinin activation. Kinin activation may 
inhibit adhesion of neutrophils, monocytes and platelets 
to endothelium, increasing vascular permeability. 
If these activation mechanisms overwhelm haemosta- 
tic inhibitors and thrombin formation is uncontrolled, 
thrombus formation is potentiated and subsequent 
organ failure may develop. 
Thrombus formation, contact system activation and 
endothelial leasin (liberating tPA) all activate fibrinoly- 
sis. If plasmin activation is extensive, some coagulation 
factors are severely depleted. 
Clinical Findings 
Although the classic presentation of DIC may include 
fever, acidosis, hypoxaemia, proteinuria, bleeding, 
shock and evidence of multiple organ failure (Bick 1985; 
Slappendel 1988b), it is essential to note that there is 
considerable variability in clinical findings. DIC can be 
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acute or chronic depending on whether the underlying 
illness is acute (decompensated DIC) or chronic (com- 
pensated DIC). The clinical manifestations may also 
differ among diseases, from patient o patient, and even 
chronologically in the same patient. Physical findings 
that accompany microthrombosis-associated DIC are 
associated with decreased organ perfusion. Renal 
thrombosis leads to severe renal dysfunction, common 
sequelae in horses with DIC (Carlson 1990). Gastro- 
intestinal thrombosis results in acute colic secondary to 
submucosal necrosis and ulceration, a severe com- 
plicating event in equine patients with primary 
gastrointestinal disease. This results in spontaneous 
gastrointestinal haemorrhage clinically expressed as 
gross or occult faecal blood (Carlson 1990). In acute 
DIC, bleeding may occur at puncture sites, intravenous 
catheter sites, and surgical wounds (Bick 1982; Morris 
1988; Carlson 1990). Large vessel bleeding sites are 
particularly prone to haematoma formation. The result- 
ing pressure on other vital tissues may compound the 
clinical problem (Ampel et al. 1985). Prominent clinical 
manifestations in horses are the tendencies to major 
vessel thrombosis, especially after catheterisation, and 
thrombosis of smaller cutaneous blood vessels 
manifested by arborising subcutaneous 'cords' (Morris 
1988). Melena or haematochezia are seen mostly in 
ruminants and dogs with DIC (Slappendel 1988b; 
Carlson 1990). Digital ischaemia, subsequent to micro- 
thrombosis, frequently accompanies DIC in horses and 
plays a key role in the development of laminitis 
(McClure and McClure 1982; Holland et al. 1986). 
Pulmonary function may also be compromised by mic- 
rovascular thrombosis in DIC, causing tachypnoea and 
hypoxaemia. Cerebral microvascular thrombosis might 
lead to altered consciousness, convulsion and/or coma 
(Carlson 1990). Compensated DIC develops in patients 
with illness that produces a low-grade or intermittent 
procoagulant release stimulus. This allows longer time 
periods during which consumed or degraded coagu- 
lants, anticoagulant proteins, and platelets may be 
replenished. This compensated state may become 
unbalanced by stress, concurrent diseases, or worsening 
of the primary disease. Veterinary clinicians rarely see 
patients in the early phases of DIC. Fulminant DIC is 
more likely with resultant poor prognoses. 
Laboratory Findings 
Laboratory results vary according to the underlying 
cause of DIC and the evolution of the process. Many 
newer analytes have become available for evaluating 
patients with DIC; however, many of these are not, as 
yet, validated for veterinary use. The diagnosis of DIC 
cannot be achieved with a single test result and it is not 
possible to define which alterations are pathognomonic 
for DIC. But, the tests described below are helpful to 
diagnose DIC and to monitor therapy. 
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Red Cell Fragmentation 
Schistocyte or fragmentocyte formation is usually 
abundant in patients with low-grade DIC, but as only 
occasionally seen in fulminant DIC. The presence of 
fragmentocytes may also be seen in a variety of con- 
ditions such as MAHA, Heinz body anaemia, iron 
deficiency, and may even be seen as spurious finding of 
blood smear preparation (Slappendel 1988b). 
Thrombocytopenia and~or Thrombopathia 
The platelet count is typically decreased inDIC; though 
the percentage decrease may be quite variable. Platelet 
counts are often elevated as a non-specific nflammatory 
response. Decreased platelet numbers may, therefore, 
be relative. Platelet function tests including the 
template bleeding time and platelet aggregation are 
abnormal, as a late stage finding in patients with DIC. 
Therefore, platelet function in DIC patients may be 
variable (Bick 1988; Muller 1989). Increased platelet 
turnover and decreased survival is common with DIC 
patients; platelet factor 4, fl thromboglobulin, and TxA2 
concentrations are markers of overall platelet reactivity 
and release. These concentrations are usually elevated 
in DIC patients (Bick 1988). 
Tests of Secondary Haemostasis 
The prothrombin time (PT) is anticipated to be pro- 
longed in DIC for multiple reasons. The PT depends 
upon the ultimate conversion of fibrinogen into fibrin. 
In DIC there is usually consumption-induced hypofibri- 
nogenaemia and increased FDPs, which interfere with 
fibrin monomer polymerisation. Also lysis of factors V 
(and numerous other factors) by plasmin could prolong 
the PT. However, a PT within the reference interval in 
DIC patients may be observed as the underlying process 
progresses from peracute to acute; PT changes from a 
shortened test-  activation of factors X and prothrombin 
(II) - through the reference interval and, finally, becom- 
ing prolonged. 
The activated partial thromboplastin time (APTf) is 
also anticipated to be prolonged in fulminant DIC 
because of plasmin-induced biodegradation of coagu- 
lation factors. However, APTT may not be prolonged in 
DIC patients for the same reasons mentioned above in 
reference to PT. 
Thrombin time (q'T) or Reptilase time, tests of the 
final common coagulation pathway, are anticipated to 
be prolonged in DIC. Both tests may be prolonged by 
circulating FDPs and subsequent interference with 
fibrin monomer polymerisation (Jandl 1991). Appropri- 
ate results for these tests can be observed in DIC 
patients when FDP accumulations are a relatively late 
happening. 
Coagulation factor assays provide insufficient clini- 
cally useful information in patients with DIC (Feldman 
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1981). Fibrinogen concentration is dramatically 
decreased in patients with fulminant DIC (Feldman 
1981). However, normal or elevated concentrations 
may be seen in patients with early and compensated 
DIC - where fibrinogen production exceeds degra- 
dation (McKay 1983). In addition, most of the under- 
lying disease processes are actively inflammatory 
(Feldman 1981; Slappendel 1988b). This results in 
elevated concentrations of fibrinogen early in the 
process. Fibrinogen concentration is not reliable for 
diagnosis of DIC in horses, since horses rarely develop 
hypofibrinogenaemia (Johnstone and Crane 1986). 
However, return of fibrinogen concentration i other 
species towards the reference interval may be the best 
prognosticator f therapeutic success. 
Thrombin Activation 
Coagulation activation markers as thrombin-anti- 
thrombin III complexes (TAT) are widely used in 
human medicine to observe thrombin activation in 
hypercoagulable state (Asakura et al. 1991). Thrombin- 
ATIII complex determination has been performed in 
veterinary medicine (Monreal et al. 1993). 
Production of fibrinopeptide A is related to thrombin 
activation. It is usually elevated in patients with DIC as 
well as in a wide variety of other micro- or macrovas- 
cular thrombotic events. The test provides an overall 
assessment of haemostasis activation indicating the 
presence of thrombin-induced fibrinogen proteolysis. 
Disappearance of fibrinopeptide A may aid in assessing 
the efficicacy of therapy in DIC (Jensen and Ens 1991). 
Determination of an effective test of prothrombin 
activation markers - F1 + 2 fragments - was not shown 
to be useful in rabbits (Monreal et al. 1993). 
Soluble fibrin monomer (FM) - the complex of FDPs 
and fibrin monomer - can be detected by protamine 
gelation and agglutination tests. Positive results may 
appear in patients with a variety of diseases which might 
be associated with DIC but definite proof of DIC 
diagnosis is still lacking. Therefore, the tests for FM are 
valuable mainly as broad screening tests (Slappendel 
1988b). Recently, an immunological assay was devel- 
oped in human medicine which can directly quantify the 
amount of soluble fibrin monomers (SF) formed in 
blood. This study examined this assay system in the 
diagnosis of DIC and found that it was a good indicator 
for both fibrin formation and for DIC. It also correlated 
well with serum levels of FDPs (Nakagawa et al. 1994). 
Fibrinolysis 
Elevated FDP concentrations are late-stage findings in 
most patients with DIC (Feldman 1981; Slappendel 
1988b). FDPs are the result of plasmin biodegradation 
of fibrinogen or fibrin, and thus are indicative of plasmin 
presence in the circulation. This may be a result of 
primary fibrinolysis (rare in most animal species includ- 
ing human) or secondary as in DIC. FDP concentration 
results are variable and inconsistent in cats (O'Rourke 
et al. 1982). Canine patients with FDP concentrations of 
10 #g/ml or more are considered to have increased 
fibrinolysis; the concentration may be as high as 320 ~g/ 
ml in overt DIC patients (Slappendel 1988b). FDPs 
greater than 40 #g/ml in equine patients are only 
suggestive of DIC (Morris 1988). In the horse, inter- 
preting FDP concentrations is difficult and their 
presence is certainly not pathognomonic for DIC. 
Newer analytes for diagnosis of DIC such as quantifi- 
cation of B-fl 15-42 fragments and distinct fibrinogen or 
fibrin degradation products are widely used in human 
medicine, and begin to be utilised in veterinary medi- 
cine (Monreal et al. 1993). Fibrinogen degradation 
products (FgDP) and fibrin degradation products 
(FbDP) by ELISA have been suggested to be reliable 
and sensitive assays for diagnosis of DIC (Jensen and 
Ens 1991; Bick and Backer 1992). As yet, however, 
these analytes have not been validated for routine use in 
veterinary medicine. The radioimmunoassay for B-fl 
15-42 and related peptides, when performed in con- 
junction with fibrinopeptide A, can aid in the differen- 
tial diagnosis of DIC versus primary fibrinolysis (Bick 
1988; Muller 1989). B-fl 15-42 and related peptides 
result from cleavage of B-fl peptides from the B-fl chain 
of fibrinogen by plasmin (Fig. 2). Elevation of B-fl 15-42 
and related peptides without concurrent fibrinopeptide 
A elevation is strong evidence for primary fibrinolysis, 
whereas the elevation of both is evidence of DIC (Bick 
1988). 
Plasminogen and tr-antiplasmin concentrations may 
be reduced in DIC. But enhanced fibrinolysis may be 
assessed by plasmin-~2-antiplasmin complex (PIC) 
quantification i human medicine. It has been observed 
Thrombin 
Fibrinogen ~ ~ ~ibrinopeptide 
"~ B-Beta chain 
--'. Plasmin 
Fragments X,Y,D,E (Fragment B-Beta 15-42 
~. other peptides ,,) 
Fig. 2. Formation of fragment B-beta 15-42 from fibrin(ogen). 
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that the highest concentrations of PIC corresponded to
DIC induced by acute promyelocytic leukaemia (APL), 
the concentrations being relatively lower than in DIC 
induced by sepsis. 
Plasminogen activator inhibitors (PAl) are deter- 
mined in human medicine. A significant elevation in 
active PAI was observed in DIC due to acute leukae- 
mia, chronic myeloid leukaemia nd sepsis, but not in 
APL, non-Hodgkin lymphoma, and cancer. Active PAI 
was higher in patients with multiple organ failure 
(MOF) than in those without MOF whereas PIC was 
lower in patients with this complication. Thus, the 
balance of coagulation and fibrinolysis varied according 
to the underlying cause of DIC; APL having more 
activation of fibrinolysis, whereas sepsis had greater 
activation of coagulation. It is suggested that the 
inhibition of secondary fibrinolytic activation plays an 
important role in the progression of MOF (Asakura et 
al. 1994). 
Coagulation I hibitors 
Functional ATIII concentration i patients with DIC is 
commonly decreased (Tanaka et al. 1986). ATIII is a 
regulator of several procoagulation proteases including 
thrombin, factors IXa, Xa, XIa, XIIa and plasma KK 
(Green 1988; High 1988). Although a diagnosis of DIC 
can not be made from ATIII concentrations, monitor- 
ing ATIII activity is important in the management of
DIC especially prior to heparin therapy and is helpful in 
prognosing clinical recovery (Gerhards 1987; Green 
1988). Antithrombin III activity was not a useful coindi- 
cator of DIC in cats infected with feline infectious 
peritonitis (Boudreaux et al. 1989). This might be due to 
increased hepatic synthesis of ATIII and decreased 
catabolism secondary to diffuse vasculitis (ATIII may 
be rendered non-functional nd thus unable to inhibit 
activated serine proteases) (Boudreaux et al. 1989). 
Determinations of protein C pathway activation and 
contact system activation such as APC:PCI complex, 
KK:PCI complex, and APC-cd-antitrypsin complex, 
have been accomplished in human medicine in relation 
to septic shock and early coagulation activation 
(Alcaraz et al. 1995). In acute malaria, reduction in 
plasma AT III concentrations, protein C, factor XII and 
prekallikrein (PK) activities were observed (Clemens et 
al. 1994). 
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Thromboelastography 
Thromboelastography (TEG), is a less commonly avail- 
able technique used to assess haemostatic function. 
Analysis of TEG yields qualitative information about 
platelet function, thromboplastin, and their interaction 
with the intrinsic coagulation cascade to form a stable 
clot. Additional information is obtained about fibrino- 
gen and factor XIII concentrations as well as the 
fibrinolytic system. TEG is more sensitive and accurate 
than the traditional universal coagulation tests (PT, 
APTT) in revealing haemostatic disorders (Bigeleisen 
and Kang 1991). The test has also been used in diagnosis 
of DIC in dogs (Johnson et al. 1983). 
It is not possible, as yet, to establish minimal criteria 
for an early diagnosis of DIC, although such criteria 
may clearly improve therapy and the outcome of some 
patients. But DIC diagnosis is frequently based on a 
constellation of laboratory findings, such as thrombo- 
cytopenia, hypofibrinogenaemia and high concentra- 
tions of FDPs (Mora et al. 1995), red blood cell 
fragmentation, thrombocytopenia, prolonged coagu- 
lation tests and increased FDPs concentrations 
(Chuamsumrit et al. 1993. It is also suggested that the 
compensated form of activation of intravascular coagu- 
lation may be diagnosed by a decrease in ATIII, an 
increase in TAT, the appearance of FM and D-dimers 
(FbDP). Prolonged bleeding time, PT, PTT and hypo- 
fibrinogenaemia are found in severe DIC (Schneider 
1994). 
Rational Therapy 
The treatment of DIC remains controversial. There is a 
global perception that therapy is often futile and that 
most patients die. Difficulties with therapeutics in DIC 
are extant because of the diverse aetiologies and clinical 
manifestations. Simply stated, therapy should be highly 
individualised. 
The therapy of acute DIC should be sequential and 
have a logical strategy (Table 4). The most important 
therapeutic modality is removal of the inciting cause. If 
the removal of the inciting cause is not possible 
(exemplified by widespread metastatic disease) a speci- 
fic approach may be indicated (Ruehl et al. 1982). 
Supportive therapy must be aggressively instituted con- 
comitant with therapy for treatment or mitigation of the 
underlying event. 
Fibronectin 
Fibronectin is one of the endothelial adhesion glyco- 
protiens which has been recently used as a molecular 
marker for endothelial injury (Toschi et al. 1991; Saleh 
et al. 1992). The concentration of fibronectin was found 
to be decreased incanine patients with DIC (Feldman et 
al. 1985). 
Fluid Therapy 
Fluid therapy is indicated to correct hypovolaemia, for 
prevention or alleviation of vascular stasis, and for 
dilution of thrombin, FDPs and activators of fibrinolysis 
(Ruehl et al. 1982). The use of electrolytes and/or 
volume expanders uch as plasma protein fractions, 
albumin, dextran 70, hdyroxyethyl starch and hyper- 
tonic saline solution combined with colloids (Ruehl et 
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Table 4. Sequential therapy infulminant disseminated intravascular 
coagulation 
1. Remove inciting cause 
Use of antimicrobial or antineoplastic therapy 
Control shock 
Volume replacement 
Glucocorticoids, antimicrobials (endotoxaemia) 
2. Inhibit haemostasis 
Application of heparin or 
Other anticoagulant drugs (hirudin, gabexate) 
Antiplatelet agents 
3. "Specific blood component therapy 
Platelet concentrates - not currently applicable in veterinary 
medicine 
Packed red cells (washed) 
Antithrombin concentrates 
or frozen plasma 
Cryoprecipitate 
4. Inhibit fibrinolysis (?a) 
Epsilon-aminocaproic ac d
Transexamic a id 
ATIII-dependent activity. Preliminary studies indicated 
that LMWH are effective in treatment ofDIC and have 
less risk of haemorrhage (Oguma et al. 1990). Recently, 
it has been observed that administration f LMWH to 
horses may avoid some undesirable ffects related to 
standard heparin administration, such as erythrocyte 
agglutination (Monreal et al. 1995). 
Newer agents with potential therapeutic benefits for 
fulminant and compensated DIC are recombinant hiru- 
din and gabexate mesilate (Hauptmann and Bruggener 
1988; Umeki et al. 1988). These drugs are capable of 
inhibiting thrombin or factor Xa in the absence of 
ATIII. Experimental studies proved that hirudin 
(Nowak and Markwardt 1991) and gabexate mesilate 
(Suzuki et al. 1988) inhibit different triggering mechan- 
isms for DIC induced by endotoxins. Further studies in 
the use of these products in veterinary medicine might 
affect morbidity and mortality from endotoxin-induced 
DIC. An orally active new specific inhibitor of factor 
Xa, DX-9065a, has been studied against wo kinds of 
experimental DIC in rats (Yamazaki et al. 1994). 
air is questionable if inhibition of fibrinolysis n a patient with 
disseminated intravascular coagulation is indicated. It may, in fact, be 
problematic and contraindicated. 
al. 1982; Concannon et al. 1992; Zoran et al. 1992) 
depend upon the primary disease, blood pH and 
electrolyte and hydration status of the patient. 
Antiplatelet Aggregant Therapy 
This has been used in patients with compensated DIC 
(Ruehl et al. 1982; Morris 1988; Slappendel 1988b). 
Acetylsalicylic acid inhibits platelet aggregation and 
blocks TxA2 release (Yao et al. 1991). However, plate- 
let inhibitors hould not be used in patients with severe 
thrombocytopenia (Ruehl et al. 1982). 
Coagulation I hibitors 
Heparin is the most common anticoagulant used in 
correction of DIC. However, it has a limited effect 
depending on the availability of functional patient 
ATIII. The anticoagulant effect of heparin is due to its 
ability to form complexes with plasma ATIII, potenti- 
ating the action of the complex to neutralise thrombin, 
factors Xa, XIIa, XIa, as well as plasmin, KK, com- 
plement and trypsin (Rosenberg 1975; Green 1988). 
Administration of high-dose heparin may increase the 
risk of haemorrhage in patients with acute DIC. 
Heparin therapy can be successful incompensated DIC 
when functional ATIII concentrations are available 
(Ruehl et al. 1982). Transfusion of fresh plasma would 
provide ATIII and other serine protease inhibitors and 
subsequent administration f low doses of heparin may 
sustain appropriate haemostasis (Wisecarver and Haire 
1989; Welch et al. 1992). Heparin may be added to the 
container of fresh frozen plasma and incubated, to 
ensure acontinuous ATIII infusion and avoiding ATIII 
depletion (Feldman 1990). Low-molecular-weight 
heparins (LMWH) are obtained from standard heparin. 
They have greater inhibitory effects on factor Xa than 
on thrombin, less interaction with platelets, and may 
have potentially new therapeutic applications (Samama 
and Babinet 1991). Their mode of action on the haemo- 
static system is based in their anti-factor Xa and IIa 
Blood Product Therapy 
This is indicated if haemorrhage occurs. This form of 
therapy necessitates the ability to continually assess the 
patient's haemostatic system. The severity of blood loss, 
thrombocytopenia, hypofibrinogenaemia, andcoagulo- 
pathy, indicates the selection of blood products. Packed 
red cells, platelet concentrates, platelet rich plasma, 
fresh frozen plasma, cryoprecipitate, or fresh whole 
blood may be considered (Mora et al. 1955). In patients 
that appear to be clinically stable, administration of
fresh or stored frozen plasma or cryoprecipitate may be 
indicated. It has been proposed that administration f 
blood products to a patient with ongoing DIC and 
microvascular thrombosis carries the risk of plasmin 
biodegradation f the administered coagulation factors 
(Bick et al. 1976; Bick 1988). Experimental dministra- 
tion of recombinant human activated protein C has also 
been studied in tissue thromboplastin-induced dis-
seminated intravascular coagulation (DIC) in rabbits 
(Katsura et al. 1994). The use of ATIII concentrates in 
human medicine is not thoroughly discussed in relation 
to the clinical improvement observed (Lechner and 
Kyrle 1995) ' . . .  the doses [of ATIII] applied in adult 
intensive care patients with septicaemia does not appear 
to improve outcome in terms of mortality' (van Beek et 
al. 1994). 
Disseminated Intravascular Coagulation (DIC) 223 
Fibrinolytic Inhibitors 
Fibrinolytic inhibitors are rarely indicated, unless 
secondary fibrinolysis continues to biodegrade plasma 
proteins. If this occurs, antifibrinolytic (e-aminocaproic 
acid) therapy may be considered. It is, however, import- 
ant to note that this therapy is contraindicated for 
patients with ongoing DIC, as these patients are depen- 
dent on fibrinolysis to clear microthrombi. Also anti- 
fibrinolytic therapy should never be applied unless 
increased fibrinolytic activity and subsequent haemor- 
rhage have been documented. Tranexamic acid has 
recently been used as a potent antifibrinolytic agent 
(Takada et al. 1990). 
For effective therapy of DIC and to avoid complicat- 
ing the existing condition, therapy should be monitored. 
Return of fibrinogen concentration, ATIII concentra- 
tion, platelet numbers, and PT and APTT towards 
reference intervals are among the most consistent 
signals of therapeutic success. It should be noted that 
this statement is in direct opposition to the myth of 
prolonging the universal tests of coagulation (PT and 
AP'I-T) towards ome predetermined time. 
Finally, preventive measures to reduce morbidity and 
mortality from endotoxaemia-induced DIC in horses 
have been studied. Studies involved feeding horses a 
diet enriched with ~-3 fatty acids. These fatty acids alter 
the cell-membrane phospholipid composition. Results 
indicated that mononulcear phagocytes from horses on 
this diet have reduced ability to produce inflammatory 
mediators including eicosanoids and TNF, in response 
to endotoxins in vitro (Henry et al. 1991; Morris et al. 
1991). 
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